Clostridioides difficile and colorectal cancer: a dangerous liaison.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
Many colorectal diseases depend on complex interactions between several pathophysiological factors, including the intestinal microbiota. In recent years, the widespread use of antibiotics has been recognized as a main cause of intestinal dysbiosis and a favouring factor for Clostridioides difficile infection. The latter, in addition, causes infectious diarrhoea, pseudomembranous colitis, and toxic megacolon by means of its toxins (A and, especially, B), is characterized by frequent relapses; thus, its persistence in a host may be long-lasting. Based on recent experimental evidence, here we analyse the possibility that, similarly to other bacteria, Clostridioides difficile may be considered a potential carcinogen for colorectal cancer.
Identifiants
pubmed: 37505976
doi: 10.1097/MEG.0000000000002615
pii: 00042737-202309000-00009
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
985-988Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012; 13:260–270.
Gubatan J, Boye TL, Temby M, Sojwal RS, Holman DR, Sinha SR, et al. Gut microbiome in inflammatory bowel disease: role in pathogenesis, dietary modulation, and colitis-associated colon cancer. Microorganisms 2022; 10:1371.
Patangia DV, Anthony Ryan C, Dempsey E, Paul Ross R, Stanton C. Impact of antibiotics on the human microbiome and consequences for host health. Microbiologyopen 2022; 11:e1260.
Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 2015; 26:26191.
Ong GK, Reidy TJ, Huk MD, Lane FR. Clostridium difficile colitis: a clinical review. Am J Surg 2017; 213:565–571.
Giles J, Roberts A. Clostridioides difficile: current overview and future perspectives. Adv Protein Chem Struct Biol 2022; 129:215–245.
Zilberberg MD, Shorr AF, Wang L, Baser O, Yu H. Development and validation of a risk score for Clostridium difficile infection in medicare beneficiaries: a population-based cohort study. J Am Geriatr Soc 2016; 64:1690–1695.
De Roo AC, Regenbogen SE. Clostridium difficile infection: an epidemiology update. Clin Colon Rectal Surg 2020; 33:49–57.
Suetens C, Latour K, Kärki T, Ricchizzi E, Kinross P, Moro ML, et al.; Healthcare-Associated Infections Prevalence Study Group. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Euro Surveill 2018; 23:1800516.
Magill SS, O’Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, et al.; Emerging Infections Program Hospital Prevalence Survey Team. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med 2018; 379:1732–1744.
Haque M, Sartelli M, McKimm J, Abu Bakar M. Health care-associated infections - an overview. Infect Drug Resist 2018; 11:2321–2333.
Nanwa N, Kendzerska T, Krahn M, Kwong JC, Daneman N, Witteman W, et al. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol 2015; 110:511–519.
Kordus SL, Thomas AK, Lacy DB. Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics. Nat Rev Microbiol 2022; 20:285–298.
Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995; 95:2004–2011.
Kuehne SA, Collery MM, Kelly ML, Cartman ST, Cockayne A, Minton NP. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J Infect Dis 2014; 209:83–86.
Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis 2021; 21:456.
van Dorp SM, Kinross P, Gastmeier P, Behnke M, Kola A, Delmée M, et al. Standardised surveillance of Clostridium difficile infection in European acute care hospitals: a pilot study, 2013. Euro Surveill 2016; 21:pii=30293.
Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health 2019; 9:010407.
Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 2014; 14:1208–1219.
Hensgens MP, Goorhuis A, Dekkers OM, van Benthem BH, Kuijper EJ. All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clin Infect Dis 2013; 56:1108–1116.
Olsen MA, Stwalley D, Demont C, Dubberke ER. Clostridium difficile infection increases acute and chronic morbidity and mortality. Infect Control Hosp Epidemiol 2019; 40:65–71.
Tariq R, Law CCY, Khanna S, Murthy S, McCurdy JD. The impact of Clostridium difficile infection on mortality in patients with inflammatory bowel disease: a systematic review and metaanalysis. J Clin Gastroenterol 2019; 53:127–133.
Singh T, Bedi P, Bumrah K, Singh J, Rai M, Seelam S. Updates in treatment of recurrent Clostridium difficile infection. J Clin Med Res 2019; 11:465–471.
Alfayyadh M, Collins DA, Tempone S, McCann R, Armstrong PK, Riley TV, et al. Recurrence of Clostridium difficile infection in the Western Australian population. Epidemiol Infect 2019; 147:e153.
Martin JSH, Eyre DW, Fawley WN, Griffiths D, Davies K, Mawer DPC, et al. Patient and strain characteristics associated with Clostridium difficile transmission and adverse outcomes. Clin Infect Dis 2018; 67:1379–1387.
Perez R, Khanna S, Tillotson GS, Lett JE 2nd, Prince MA, Lattimer C. Reducing recurrence and complications related to Clostridioides difficile infection: a panel discussion summary. Prof Case Manag 2022; 27:277–287.
Sensini A, Marroni M, Bassotti G, Farinelli S, D’Alò F, Gentili AM, et al. Clostridium difficile-associated reactive arthritis in an HLA-B27 negative male. J Clin Gastroenterol 1993; 16:354–355.
Bassotti G, Macchioni L, Corazzi L, Marconi P, Fettucciari K. Clostridium difficile-related postinfectious IBS: a case of enteroglial microbiological stalking and/or the solution of a conundrum? Cell Mol Life Sci 2018; 75:1145–1149.
Fukugaiti MH, Ignacio A, Fernandes MR, Ribeiro Júnior U, Nakano V, Avila-Campos MJ. High occurrence of Fusobacterium nucleatum and Clostridium difficile in the intestinal microbiota of colorectal carcinoma patients. Braz J Microbiol 2015; 46:1135–1140.
Zheng Y, Luo Y, Lv Y, Huang C, Sheng Q, Zhao P, et al. Clostridium difficile colonization in preoperative colorectal cancer patients. Oncotarget 2017; 8:11877–11886.
Magat EM, Balanag GA, Carino AM, Fellizar A, Ortin TS, Guevarra L Jr, et al. Clostridioides difficile antibody response of colorectal cancer patients versus clinically healthy individuals. Biosci Microbiota Food Health 2020; 39:123–127.
Lee S, Jang EJ, Jo J, Park SJ, Ryu HG. Long-term impacts of appendectomy associated with increased incidence of inflammatory bowel disease, infection, and colorectal cancer. Int J Colorectal Dis 2021; 36:1643–1652.
Wilson MR, Jiang Y, Villalta PW, Stornetta A, Boudreau PD, Carrá A, et al. The human gut bacterial genotoxin colibactin alkylates DNA. Science 2019; 363:eaar7785.
Fiorentini C, Carlini F, Germinario EAP, Maroccia Z, Travaglione S, Fabbri A. Gut microbiota and colon cancer: a role for bacterial protein toxins? Int J Mol Sci 2020; 21:6201.
Piciocchi A, Germinario EAP, Garcia Etxebarria K, Rossi S, Sanchez-Mete L, Porowska B, et al. Association of polygenic risk score and bacterial toxins at screening colonoscopy with colorectal cancer progression: a multicenter case-control study. Toxins (Basel) 2021; 13:569.
Scott N, Whittle E, Jeraldo P, Chia NA. systemic review of the role of enterotoxic Bacteroides fragilis in colorectal cancer. Neoplasia 2022; 29:100797.
Tortora SC, Bodiwala VM, Quinn A, Martello LA, Vignesh S. Microbiome and colorectal carcinogenesis: linked mechanisms and racial differences. World J Gastrointest Oncol 2022; 14:375–395.
Pradhan R, Ngo PA, Martínez-Sánchez LD, Neurath MF, López-Posadas R. Rho GTPases as key molecular players within intestinal mucosa and GI diseases. Cells 2021; 10:66.
López-Posadas R, Stürzl M, Atreya I, Neurath MF, Britzen-Laurent N. Interplay of GTPases and cytoskeleton in cellular barrier defects during gut inflammation. Front Immunol 2017; 8:1240.
Bassotti G, Fruganti A, Maconi G, Marconi P, Fettucciari K. Clostridioides difficile infection in patients with inflammatory bowel disease may be favoured by the effects of proinflammatory cytokines on the enteroglial network. J Inflamm Res 2021; 14:7443–7453.
Boeriu A, Roman A, Fofiu C, Dobru D. The current knowledge on Clostridioides difficile infection in patients with inflammatory bowel diseases. Pathogens 2022; 11:819.
Bassotti G, Fruganti A, Stracci F, Marconi P, Fettucciari K. Cytotoxic synergism of Clostridioides difficile toxin B with proinflammatory cytokines in subjects with inflammatory bowel diseases. World J Gastroenterol 2023; 29:582–596.
Mileto SJ, Jardé T, Childress KO, Jensen JL, Rogers AP, Kerr G, et al. Clostridioides difficile infection damages colonic stem cells via TcdB, impairing epithelial repair and recovery from disease. Proc Natl Acad Sci USA 2020; 117:8064–8073.
Quaglio AEV, Grillo TG, De Oliveira ECS, Di Stasi LC, Sassaki LY. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol 2022; 28:4053–4060.
Nagao-Kitamoto H, Kitamoto S, Kamada N. Inflammatory bowel disease and carcinogenesis. Cancer Metastasis Rev 2022; 41:301–316.
Drewes JL, Chen J, Markham NO, Knippel RJ, Domingue JC, Tam AJ, et al. Human colon cancer-derived Clostridioides difficile strains drive colonic tumorigenesis in mice. Cancer Discov 2022; 12:1873–1885.
Chandrasekaran R, Lacy DB. The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev 2017; 41:723–750.
Fettucciari K, Ponsini P, Gioè D, Macchioni L, Palumbo C, Antonelli E, et al. Enteric glial cells are susceptible to Clostridium difficile toxin B. Cell Mol Life Sci 2017; 74:1527–1551.
Fettucciari K, Macchioni L, Davidescu M, Scarpelli P, Palumbo C, Corazzi L, et al. Clostridium difficile toxin B induces senescence in enteric glial cells: a potential new mechanism of Clostridium difficile pathogenesis. Biochim Biophys Acta Mol Cell Res 2018; 1865:1945–1958.
Fettucciari K, Fruganti A, Stracci F, Spaterna A, Marconi P, Bassotti G. Clostridioides difficile toxin B induced senescence: a new pathologic player for colorectal cancer? Int J Mol Sci 2023; 24:8155.
Fettucciari K, Marguerie F, Fruganti A, Marchegiani A, Spaterna A, Brancorsini S, et al. Clostridioides difficile toxin B alone and with pro-inflammatory cytokines induces apoptosis in enteric glial cells by activating three different signalling pathways mediated by caspases, calpains and cathepsin B. Cell Mol Life Sci 2022; 79:442.